Peer-reviewed work from ImmuneT-ME partners
Aung MMK, et al. Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib. Hemasphere. 2026 Apr 16;10(4):e70345.
Wahnschaffe L, et al. Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression. Nat Commun. 2026 Mar 9;17(1):2319.
Braun T, et al. Characteristics, patterns of care and outcomes of patients with T-cell lymphoma-associated hemophagocytic lymphohistiocytosis: a single-center retrospective analysis. Leuk Lymphoma. 2026 Apr;67(5):1156-1159.
Ianevski A, et al. Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer Res. 2026 Jan 16;86(2):295-309.
Dechow A, et al. Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia. Leukemia. 2025 Jun;39(6):1435-1448.
Braun T, et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat Med. 2025 Apr;31(4):1145-1153.